Explore our 🎯 Q1 2026 Psychedelic Pipeline Bullseye Charts.

Sign in Join

May 12 – 18, 2025

Pα+ Psychedelic Bulletin #197

Psychedelic Alpha ↗

  • Bridging Promise and Prudence: Portuguese Health-Related Professions Unite to Release First National Guidelines on Psychedelic Therapy
  • Shrooms, Shots, and the Next Surgeon General: Psychedelics at the Centre of MAGA Infighting
  • ‘No One Has the Right to Speak for Us’: Religious Leaders Who Participated in Hopkins Study Push Back on Critics As Publication Nears
  • Manvir Singh Challenges the Stories Westerners Tell About Psychedelics’ Past
  • Compass Pathways Sets Expectations Ahead of June Readout
  • and more…

May 5 – 11, 2025

Pα+ Psychedelic Bulletin #196

Psychedelic Alpha ↗

  • Otsuka Eyes Psychedelic Future in Japan with New Infrastructure Drive
  • ASCP 2025 Preview: Psychedelic Therapies Dominate Clinical Psychopharmacology Agenda
  • First Look at Gilgamesh’s Phase 2a Data: Psychedelic Candidate Yields Effect Size of ~1.0, But Sparse Details
  • VA Secretary Pressed for Details on Psychedelics Plans
  • and more…

April 28 – May 4, 2025

Pα+ Psychedelic Bulletin #195

Psychedelic Alpha ↗

  • Psychedelics Namechecked in Trump Cabinet Meeting
  • Interview: Noma Therapy Raises $4.25M, Aims to Disrupt At-Home Ketamine With Insurance-Friendly Approach
  • Interview: Christian Angermayer: Keep Politics Out of Psychedelics—And Bitcoin on the Balance Sheet
  • and more…

Pα+

An insider’s guide to the business,
policy and science of psychedelics.

Basic

Free subscribers receive a weekly round-up
of news on psychedelics, as well as the occasional article.

Receive regular bulletins, articles, interviews with insiders and quick-take analysis of major stories and developments.

Monthly $20 Annually $200

Teams

Teams, groups and corporate pricing plans are available, please get in touch via email
to learn more.

Benefits

Front-row access to the psychedelics space: breaking bulletins, in-depth articles, insider interviews and sharp analysis of the moments that matter—from major trial results and funding rounds to policy shifts shaping the future. Plus, full access to our complete
archive and Library.

Learn More
  Free
Weekly Psychedelic News Feed
Occasional Articles & Free Resources
Psychedelic Bulletins (In-Depth Briefings, Multiple per Month)
Quick-Take Analysis of Major Developments
In-Depth Articles & Deep Dives
Exclusive Interviews with Insiders & KOLs
Quarterly Video Briefings
Exclusive Tools & Data Resources
Library of Primers & Explainers

Subscribe Now

Monthly $20 Annually $200

Join Today

Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and research.

Monthly $20 Annually $200

Subscribe to our
free newsletter


By signing up, you agree to our privacy policy. You can unsubscribe at any time.

Learn More About

Group, team &
corporate plans


Aside from group pricing, we also offer bespoke reports and regular briefings. Get in touch to discuss.